GENEVA, Nov 24 (Reuters) - The GAVI vaccine alliance on
Tuesday welcomed Astrazeneca's interim data on
efficiency of its COVID-19 vaccine, calling it "positive news
for the COVAX vision of equitable access" for vulnerable groups
worldwide.
Hundreds of millions of doses of the candidate vaccine have
been secured on behalf of the COVAX facility, per agreements,
the Geneva-based GAVI alliance that leads the initiative along
with the World Health Organization (WHO) said in a statement.
"Positive early data on any vaccine candidate is welcome
news – even more so when it concerns a vaccine candidate that
can be transported and delivered via traditional refrigeration
and storage methods, and the manufacturer has committed to
supply on a not-for-profit basis for the duration of the
pandemic,” GAVI CEO Seth Berkley said.
(Reporting by Stephanie Nebehay; editing by Jason Neely)
Astrazeneca (AZN)
